临床试验/NCT00660374

NCT00660374已完成2 期

Assessment of Safety and Efficacy of Insulin NPH Compared to a New Insulin Formulation on Glycaemic Control in Subjects With Type 2 Diabetes

Novo Nordisk A/S0 个研究点目标入组 402 人开始时间: 2008年2月最近更新: 2015年5月5日

适应症

干预措施

试验速览

阶段: 2 期
状态: 已完成
发起方: Novo Nordisk A/S
入组人数: 402
主要终点: HbA1c

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者记录与标识符相似试验

研究概览

简要总结

This trial is conducted in South America. This trial aims for a comparison of the safety and efficacy of insulin NPH and a new insulin formulation on blood glucose control.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Type 2 diabetes for at least 12 months
•Current NPH treatment for at least 3 months - alone or as the only insulin in combination with OADs
•Body Mass Index (BMI) less than or equal to 40 kg/m2
•HbA1c less than or equal to 9.5%
•FPG less than or equal to 12 mmol/L

排除标准

•Treatment with Glucagon-like peptide 1 mimetics or dipeptityl peptidase IV inhibitors
•Treatment with more than 1 IU/kg NPH insulin daily
•Known hypoglycaemia unawareness or recurrent major hypoglycaemia, as judged by the Investigator
•Known or suspected allergy to trial products or related products
•Receipt of any investigational drug within one month prior to this trial
•Any other condition that the Investigator feels would interfere with trial participation or evaluation of results, e.g. shiftworkers

研究组 & 干预措施

A

Active Comparator

干预措施: insulin NPH (Drug)

B

Experimental

干预措施: EX1000 (Drug)

结局指标

主要结局

HbA1c

时间窗: For the duration of the trial

次要结局

Fructosamine(For the duration of the trial)
4-point SMPG profiles(For the duration of the trial)
Incidence of hypoglycaemic episodes(For the duration of the trial)
FPG(For the duration of the trial)
Laboratory safety parameters (haematology, biochemistry and lipids)(For the duration of the trial)
Physical examination and vital signs(For the duration of the trial)
HbA1c(For the duration of the trial)
Frequency and severity of adverse events (including injection site reactions)(For the duration of the trial)

研究者

发起方

Novo Nordisk A/S

申办方类型

Industry

责任方

Sponsor

相似试验

已完成

4 期

Human Insulin NPH and Insulin Aspart in Type 1 DiabetesDiabetesDiabetes Mellitus, Type 1

NCT00597233Novo Nordisk A/S91

已完成

3 期

Comparison of Human Insulin Produced by the Current Process and the NN729 Process in Type 1 DiabetesDiabetesDiabetes Mellitus, Type 1

NCT00569400Novo Nordisk A/S241

已完成

3 期

Comparison of Insulin Detemir With NPH Insulin in Type 1 DiabetesDiabetesDiabetes Mellitus, Type 1

NCT00184665Novo Nordisk A/S501

已完成

3 期

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes MellitusDiabetesDiabetes Mellitus, Type 2

NCT02420262Novo Nordisk A/S506

已完成

3 期

Safety of Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes MellitusDiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2

NCT01709929Novo Nordisk A/S2,287